Accession Number: | 0001735276-19-000121 |
Date: | 2019-12-23 |
Issuer: | ALNYLAM PHARMACEUTICALS, INC. (ALNY) |
Original Submission Date: |
KEATING LAURIE
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
CAMBRIDGE, MA 02142
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
PERFORMANCE STOCK OPTION 2017 (RIGHT TO BUY) | 119.13 | 2019-12-23 | deemed execution date | A | 4,583 (a) | 2019-12-23 | 2028-03-01 | common stock 4,583 | $119.13 | 9,166 | direct |
ID | footnote |
---|---|
f1 | on march 1, 2018, the reporting person was granted a performance based stock option to purchase shares of alny common stock. one third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. the compensation committee of the company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of december 23, 2019. |